We just covered the 10 Best Stocks to Buy Right Now According to AI and Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) ranks 10th on this list.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company focused on developing therapies for patients suffering from rare neurological diseases
The flagship commercial product is WAKIX (pitolisant), a first-in-class medication approved by the FDA to treat excessive daytime sleepiness or cataplexy in adult patients with narcolepsy. Pitolisant functions through a novel mechanism of action that increases histamine release in the brain to promote wakefulness. Harmony is actively working to expand its market footprint by seeking regulatory approvals for pediatric narcolepsy and exploring treatments for idiopathic hypersomnia and Prader-Willi syndrome.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) recently posted impressive Q1 2026 financial results, which featured total revenues of $215.4 million, representing a 17% year-over-year growth driven by the sustained adoption of WAKIX. Management reaffirmed its full-year 2026 net revenue guidance of over $1 billion, signaling durable commercial momentum and stable market demand. The business exhibits exceptional operating leverage, converting its top-line growth into strong cash generation that comfortably funds its late-stage clinical pipeline.